Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 19/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 12/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835100 | 1.00 | NR3C1 (0.39) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL4835122 | 1.00 | NR3C1 (0.39) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL6407247 | 0.93 | NR3C1 (0.45) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL5774880 | 0.93 | NR3C1 (0.45) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL6407246 | 0.93 | NR3C1 (0.45) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL5707774 | 0.85 | NR3C1 (0.31) | NR3C1NR3C2 | |
| SCHEMBL3538722 | 0.85 | NR3C1 (0.35) | NR3C1NR3C2PGR | |
| SCHEMBL3538726 | 0.85 | NR3C1 (0.35) | NR3C1NR3C2PGR | |
| SCHEMBL3538725 | 0.85 | NR3C1 (0.35) | NR3C1NR3C2PGR | |
| SCHEMBL3532798 | 0.84 | NR3C1 (0.32) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442794-B2 | Rearranged pentanols, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-10-28 | — | — | US | disclosed |
| EP-1670778-B1 | REARRANGED PENTANOLS, A METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AG (DE) | 2006-11-15 | — | — | EP | disclosed |
| EP-1670778-A1 | REARRANGED PENTANOLS, A METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | Schering Aktiengesellschaft (DE) | 2006-06-21 | — | — | EP | disclosed |
| US-20050131226-A1 | Rearranged pentanols, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-06-16 | — | — | US | disclosed |
| WO-2005035518-A1 | REARRANGED PENTANOLS, A METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131226-A1 | Rearranged pentanols, a process for their production and their use as anti-inflammatory agents | TNF, PTGES, PTGES2 | NR3C1 190/4885NR3C2 221/4885CYP3A4 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.